搜索结果: 61-75 共查到“知识库 传染病学”相关记录1551条 . 查询时间(0.644 秒)
重症新型冠状病毒肺炎患者的临床特点及其死亡的影响因素研究
新型冠状病毒肺炎 临床特点 死亡 影响因素分析
2021/3/25
新型冠状病毒肺炎(COVID-19)传播性极强,较2003年非典型肺炎疫情更为严重,多数患者死于严重呼吸困难,目前关于重症COVID-19的研究较少。目的 分析重症COVID-19患者的临床特征及其死亡的影响因素,以为临床诊疗提供参考。方法 回顾性分析2020年2月1日—3月11日黄冈市中心医院黄冈大别山区域医疗中心重症监护室(ICU)收治的重症COVID-19患者46例,均采用常规方案治疗。收集...
新中国成立初期的抗疫斗争及其经验
新中国 成立初期 抗疫斗争 抗疫经验
2020/7/27
新中国成立初期，由于长期战乱、灾荒、医疗资源匮乏、卫生习惯差等原因，导致鼠疫、霍乱、天花、血吸虫病等传染病在我国仍不同程度发生，严重威胁人民群众的生命安全和身体健康。其中，鼠疫、霍乱和天花属于甲类烈性传染病，具有传染性强、病死率高、危害性大等特点。当时，鼠疫在东北、东南、西南的许多地区肆虐。1949年下半年，内蒙古察蒙租银地发生鼠疫疫情，并传播至河北一带。1950年初，福建华安、江西南昌、浙江温州...
了解贵港市老年人类免疫缺陷病毒感染者/艾滋病患者（HIV / AIDS）的生存状况及其影响因素，为制定有针对性的防治措施提供参考依据。方法采用回顾性队列研究，在艾滋病综合防治信息系统中选择年龄≥50岁的艾滋病毒/艾滋病患者作为研究对象，用生命表法计算生存率，Kaplan-Meier法回归生存曲线，Log-Rank检验比较不同组别生存时间的差异，Cox比例风险模型进行多因素分析。
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
Preventive medicine SARS-CoV-2 Viral infection
2020/6/11
An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally. Countermeasures are needed to treat and prevent ...
观察替诺福韦酯治疗慢性乙型肝炎的临床疗效。方法 选取2017年8月至2018年8月在揭西县人民医院内二科门诊治疗的慢性乙型肝炎患者160例，按照随机数表法将患者分为对照组和观察组，每组80例。对照组采用恩替卡韦治疗，观察组采用替诺福韦酯治疗，均治疗24周。比较两组患者治疗后的临床疗效，以及治疗前后的血清肝功能、血清炎性因子[白细胞介素-2 (IL-2)、肿瘤坏死因子-α (TNF-α)、干扰素(I...
梅里埃MALDI-TOF-MS 系统与VITEK 2 Compact 全自动微生物鉴定仪对临床常见病原菌鉴定的一致性分析
病原菌鉴定 基质辅助激光解吸电离飞行时间质谱 VITEK2Compact
2021/3/17
分析梅里埃基质辅助激光解吸电离飞行时间质谱（matrix-assisted laser desorption ionization-time of flightmass spectrometry，MALDI-TOF-MS）系统与VITEK 2 Compact 全自动微生物鉴定仪对临床常见病原菌鉴定的一致性。方法 收集福建医科大学孟超肝胆医院2018 年6 月~ 2019 年3 月来自临床不同标本分...
Structural basis for RNA replication by the SARS-CoV-2 polymerase
2019-nCoV SARS-CoV-2 COVID-19 remdesivir favipiravir polymerase RdRP virus nsp12 nsp8
2020/6/11
Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this despite an incomplete me...
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2
SARS-CoV-2 human ACE2 transgenic mouse COVID-19 pneumonia
2020/6/11
COVID-19 has spread worldwide since 2019 and is now a severe threat to public health. We previously identified the causative agent as a novel SARS-related coronavirus (SARS-CoV-2) that uses human angi...
Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture
Novel coronavirus alkaloid broad-spectrum antiviral 2019-nCoV SARS-CoV-2
2020/6/11
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined...
Key Residues of the Receptor Binding Motif in the Spike Protein of SARS-CoV-2 That Interact With ACE2 and Neutralizing Antibodies
SARS-CoV-2 cross-neutralizing antibody receptor binding motif spike protein substitution mutation
2020/6/11
Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotens...
Structural Basis for the Inhibition of SARS-CoV-2 Main Protease by Antineoplastic Drug Carmofur
SARS-CoV-2 cross-neutralizing antibody receptor binding motif spike protein substitution mutation
2020/6/11
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of...
探讨失效模式效应分析在新型冠状病毒肺炎疫情期间社区居家护理感染防控中的应用效果。方法 新型冠状病毒肺炎疫情期间（2020年1—3月）在社区健康服务中心居家护理过程中运用失效模式效应分析找出潜在失效模式并制定改进措施,比较失效模式效应分析实施前（1月18—24日）和实施后（3月1—7日）感染风险值及感染防控相关措施落实情况,统计实施期间（1月25日—2月29日）医患双方新型冠状病毒肺炎感染率和服务患...
Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19
Plasma Metabolomic Lipidomic Alterations Associated COVID-19
2020/6/11
The pandemic of the coronavirus disease 2019 (COVID-19) has become a global public health crisis. The symptoms of COVID-19 range from mild to severe conditions. However, the physiological changes asso...
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
The anti-influenza virus drug arbidol efficient inhibitor SARS-CoV-2 in vitro
2020/6/11
Since December 2019, a novel disease COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread to over 200 countries and infected over 1.50 million people includin...